Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Budget,
Health,
Industry
|
Common Drug Review and the pan-Canadian Oncology Drug Review, as they relate to health technology assessments and drug product reimbursement recommendations.
|
Policies or Program
|
Budget,
Health,
Industry
|
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
Health,
Industry,
Research and Development
|
Food and Drugs Act Modernization initiative, including the Regulatory Review of Drugs and Devices.
|
Legislative Proposal, Bill or Resolution
|
Budget,
Health,
Industry,
Intellectual Property
|
Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade.
|
Legislative Proposal, Bill or Resolution
|
Budget,
Health,
Industry,
Research and Development
|
Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products.
|
Legislative Proposal, Bill or Resolution
|
Budget,
Health,
Industry,
Research and Development
|
Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products.
|
Legislative Proposal, Bill or Resolution
|
Health,
Industry,
Research and Development,
Science and Technology
|
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
|
Policies or Program
|
Budget,
Health,
Industry,
Research and Development,
Science and Technology
|
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
|
Policies or Program
|
Budget,
Health,
Industry,
Research and Development,
Science and Technology
|
National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases and incentives for development of the treatments for rare diseases.
|
Policies or Program
|
Budget,
Health,
Industry,
Intellectual Property
|
Patent Act and Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property and approval for therapeutic products.
|
Legislative Proposal, Bill or Resolution
|
Budget,
Health,
Industry,
International Trade
|
Regulations regarding the exportation of medicines packaged and labelled for the Canadian market to countries other than Canada.
|
Policies or Program,
Regulation
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Common Drug Review and the pan-Canadian Oncology Drug Review, as they relate to health technology assessments and drug product reimbursement recommendations.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act Modernization initiative, including the Regulatory Review of Drugs and Devices.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
National Pharmacare policies and programs, including the Canadian Drug Agency Transition office, and a national rare disease strategy.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
National Pharmaceuticals Strategy, as it relates to enhanced access to orphan drugs and incentives for development of the treatments for rare disorders.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patent Act and Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property and approval for therapeutic products.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Regulations regarding the exportation of medicines packaged and labelled for the Canadian market to countries other than Canada.
|
Policies or Program,
Regulation
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: